Table 1 Characteristics of 69,460 5-year survivors in the PanCareSurFup study and number of subsequent primary gliomas and meningioma of the central nervous system.

From: Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

Factor

Exposure

Survivors (%)

Gliomaa

Meningiomaa

Overall

Overall

69,460 (100%)

279 (100%)

761 (100%)

Sex

Male

37,738 (54.3%)

154 (55.2%)

355 (46.6%)

 

Female

31,722 (45.7%)

125 (44.8%)

406 (53.4%)

Childhood

Leukaemia

16,646 (24.0%)

68 (24.4%)

335 (44.0%)

cancer

Hodgin lymphoma

6046 (8.7%)

10 (3.6%)

14 (1.8%)

type

Non-Hodgkin lymphoma

4078 (5.9%)

10 (3.6%)

31 (4.1%)

 

CNS tumourb

14,592 (21.0%)

132 (47.3%)

319 (41.9%)

 

Neuroblastoma

3178 (4.6%)

6 (2.2%)

2 (0.3%)

 

Retinoblastoma

2590 (3.7%)

9 (3.2%)

30 (3.9%)

 

Wilms tumour

4783 (6.9%)

7 (2.5%)

2 (0.3%)

 

Bone sarcoma

3173 (4.6%)

7 (2.5%)

4 (0.5%)

 

Soft-tissue sarcoma

4531 (6.5%)

18 (6.5%)

14 (1.8%)

 

Otherc

9843 (14.2%)

12 (4.3%)

2 (0.3%)

Age at

0–4 years

22,013 (31.7%)

112 (40.1%)

336 (44.2%)

childhood

5–9 years

17,672 (25.4%)

89 (31.9%)

242 (31.8%)

cancer

10–14 years

14,747 (21.2%)

52 (18.6%)

152 (20.0%)

 

15–20 years

15,028 (21.6%)

26 (9.3%)

31 (4.1%)

Country

United Kingdom

17,960 (25.9%)

142 (50.9%)

470 (61.8%)

 

France

3138 (4.5%)

27 (9.7%)

10 (1.3%)

 

Hungary

4885 (7.0%)

6 (2.2%)

22 (2.9%)

 

Italy

8966 (12.9%)

9 (3.2%)

23 (3.0%)

 

Netherlands

6044 (8.7%)

17 (6.1%)

88 (11.6%)

 

Denmark

4840 (7.0%)

10 (3.6%)

26 (3.4%)

 

Sweden

7709 (11.1%)

23 (8.2%)

21 (2.8%)

 

Norway

3783 (5.4%)

3 (1.1%)

3 (0.4%)

 

Finland

6229 (9.0%)

27 (9.7%)

65 (8.5%)

 

Iceland

275 (0.4%)

0 (0%)

3 (0.4%)

 

Slovenia

1252 (1.8%)

7 (2.5%)

19 (2.5%)

 

Switzerland

4379 (6.3%)

8 (2.9%)

11 (1.4%)

Era

<1970

8993 (12.9%)

51 (18.3%)

143 (13.8%)

childhood

1970–1979

13,479 (19.4%)

93 (33.3%)

314 (41.3%)

cancer

1980–1989

20,900 (30.1%)

90 (32.3%)

259 (34.0%)

diagnosis

1990–1999

19,260 (27.7%)

40 (14.3%)

44 (5.8%)

 

2000–2008

6828 (9.8%)

5 (1.8%)

1 (0.1%)

Attained age

<20 years

15,405 (22.2%)

106 (38.0%)

54 (7.1%)

 

20–29 years

18,877 (27.2%)

65 (23.3%)

201 (26.4%)

 

30–39 years

17,144 (24.7%)

64 (22.9%)

301 (39.6%)

 

40–49 years

10,970 (15.8%)

28 (10.0%)

150 (19.7%)

 

50+ years

7064 (10.2%)

16 (5.7%)

55 (7.2%)

Proof of

Histology

–

186 (66.7%)

372 (48.9%)

diagnosis

Clinical examination (incl.radiology)

–

51 (18.3%)

314 (41.3%)

for SPN

Unknown

–

42 (15.1%)

75 (9.9%)

  1. N number, SPN subsequent primary neoplasm, CNS central nervous system.
  2. aA total of 279 glioma and 761 meningioma SPNs were observed among 941 survivors.
  3. bCNS tumour category includes: astrocytomas (n = 6023), intracranial/intraspinal embryonal tumours (n = 1975), other gliomas (n = 1890), other specified cns tumours (n = 1657), ependymomas and choroid plexus tumour (n = 1378), unspecif. cns tumours (n = 1227), cns germ cell tumours (n = 433), unspecified (n = 9).
  4. c“Other” category includes malignant gonadal germ cell tumours (n = 2300), malignant melanomas (n = 1458), thyroid carcinomas (n = 1295), other and unspecif. carcinomas (n = 1181), other unspecif. malignant tumours (n = 641), malignant extracranial/extragonadal germ cell tumours (n = 433), skin carcinomas (n = 423), unspec. Lymphomas (n = 402), hepatoblastoma (n = 319), misc. lymphoreticular neoplasms (n = 279), other and unspecif. malignant gonadal tumours (n = 221), gonadal carcinomas (n = 200), nasopharyngeal carcinomas (n = 194), renal carcinomas (n = 124), other peripheral nervous cell tumours (n = 94), adrenocortical carcinomas (n = 86), hepatic carcinomas (n = 84), other specif. malignant tumours (n = 54), unspecif. malignant renal tumours (n = 35), unspecif. malignant hepatic tumours (n = 15), unspecified (n = 5).
Back to article page